Interference of amphiregulin and EGFRvIII expression with outcome of patients with squamous cell carcinoma of the head and neck (SCCHN) receiving cetuximab-docetaxel treatment.
I. Tinhofer
Research Funding - Merck Serono
K. F. Klinghammer
No relevant relationships to disclose
W. Weichert
No relevant relationships to disclose
M. Knoedler
Honoraria - Merck Serono
A. Stenzinger
No relevant relationships to disclose
T. C. Gauler
Honoraria - Merck Serono
V. Budach
Honoraria - Merck Serono
U. Keilholz
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono; Sanofi
Research Funding - Merck Serono